Immunoassays News and Research

RSS

Lateral flow assays detect a compound of interest in a compact, paper-based system. Tests such as pregnancy tests are based on lateral flow assays, with many more available for various compounds or even pathogens.

Diagnosis of viral infections using micro and nanoscale technologies

In a recent study, the authors provide a review on both micro- and nanoscale technologies that advanced the diagnosis of viral diseases.

3 Aug 2021

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

Researchers in Austria have conducted a study showing that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit a significantly more pronounced antibody response to one dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine than previously uninfected individuals.

3 Aug 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

A study conducted by researchers from Maryland in the United States has found no correlation between the symptoms that develop following vaccination against coronavirus disease 2019 (COVID-19) and the antibody responses that are generated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

SARS-CoV-2 test in 20 minutes with FISH

A collaboration from the University of Oxford and the University of Warwick has led to research into a novel method of viral detection through rapid fluorescence in situ hybridization (FISH) in order to effectively detect the SARS-CoV-2 virus within 20 minutes.

29 Jun 2021

Standardizable assay detects T cell responses to SARS-CoV-2 infection

Researchers in the UK have developed a high-throughput standardizable assay that accurately detects T cell responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

6 Jun 2021

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

An international team of scientists has identified a human molecule — biliverdin — as a potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) target. The binding of the heme metabolite to the N-terminal domain of SARS-CoV-2 is associated with the virus’s ability to dodge the immune system by suppressing antibody binding to the spike protein.

2 Jun 2021

Study shows CoronaVac to have high seroconversion rate after 40 days

Researchers from the Federal University of Paraná, Brazil, looked into the seroconversion rate after vaccination with the CoronaVac. Using immunoassays, they measured the immunoglobulins (IgG) for anti-nucleocapsid protein (anti-N) antibodies and anti-spike-1 (anti-S1) protein antibodies.

27 May 2021

Novel chip-based antigen test can provide ultrasensitive detection of SARS-CoV-2, influenza A

Researchers at UC Santa Cruz have developed a novel chip-based antigen test that can provide ultrasensitive detection of SARS-CoV-2 and influenza A, the viruses that cause COVID-19 and flu, respectively.

12 May 2021

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.

10 May 2021

Applications of nanoparticles in combating COVID-19

Researchers review the various properties and use of nanoparticles in targeting SARS-CoV-2 and how they could be used to develop new therapeutics and diagnostics for SARS-CoV-2.

30 Apr 2021

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

New research has been released, which focuses on the transmission and prevalence of SARS-CoV-2 in New Zealand, through a blood donor serosurvey.

22 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

In a recent study, scientists have quantified anti-SARS-CoV-2 antibody levels up to 9 months after infection.

23 Mar 2021

INTEGRA’s electronic pipettes eliminate user fatigue and improve pipetting productivity

CDI Labs – a biotechnology company based in Puerto Rico – is using INTEGRA’s VIAFLO and VOYAGER electronic pipettes to streamline workflows and improve accuracy for the development of next generation proteomics products.

From INTEGRA Biosciences 17 Mar 2021

Salivary IgG to SARS-CoV-2 after mild COVID-19

A team of researchers based in Stockholm, Sweden, has demonstrated that individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have antibodies for the disease up to nine months after acquiring the disease, even if they displayed only mild symptoms.

16 Mar 2021

Immunoassays News and Research

Further Reading

Diagnosis of viral infections using micro and nanoscale technologies

Study suggests second Pfizer-BioNTech vaccine shot may not be needed after previous SARS-CoV-2 infection

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Lack of symptoms following COVID-19 mRNA vaccination doesn't mean vaccine not working

SARS-CoV-2 test in 20 minutes with FISH

Standardizable assay detects T cell responses to SARS-CoV-2 infection

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

Study shows CoronaVac to have high seroconversion rate after 40 days

Novel chip-based antigen test can provide ultrasensitive detection of SARS-CoV-2, influenza A

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

Applications of nanoparticles in combating COVID-19

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Immunoassay heterogeneity and implications for SARS-CoV-2 serosurveillance

INTEGRA’s electronic pipettes eliminate user fatigue and improve pipetting productivity

Salivary IgG to SARS-CoV-2 after mild COVID-19

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

Domestic dogs unlikely to transmit SARS-CoV-2, say researchers

Novel gel electrophoresis method for MS-based quantification of protein biomarkers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News